Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Tapinarof

Drug class: Aryl Hydrocarbon Receptor Agonist

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Tapinarof used for?
The FDA-approved label (Vtama, Organon LLC, May 28, 2025) says: “VTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults. the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. 1.1 Plaque Psoriasis VTAMA ® cream is indicated for the topical treatment of plaque psoriasis in adults. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Tapinarof have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Tapinarof?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Tapinarof been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Tapinarof?
1 company lists prescription products of Tapinarof in the FDA NDC Directory, including Organon LLC.

What Tapinarof is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

VTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults. the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. 1.1 Plaque Psoriasis VTAMA ® cream is indicated for the topical treatment of plaque psoriasis in adults. …

— FDA label: Vtama, Organon LLC, effective May 28, 2025. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Forms and how it is given

Dosage formsCream
RouteTopical
Prescription products1 in the FDA NDC Directory
Brand namesVtama

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Tapinarof, by strength and form
Strength and formGeneric or brandPharmacies pay
tapinarof 1%
cream
Brand: Vtama $25.25 per gram

NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA215272
VTAMA
Organon LLCMay 23, 2022 1, latest December 12, 2024
2024: Efficacy

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2602301, 2602306
SPL set ID of the quoted label9309d20f-8cd4-4c96-93fa-7f730e83c7ab
FDA labels (SPL)1
FDA applicationsNDA215272
Active ingredients (FDA)TAPINAROF

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Vtama, Organon LLC, effective May 28, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers